Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1661 to 1670 of 2603 total matches.

Salmeterol

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 1994  (Issue 921)
FOR ASTHMA Canister Contents Drug Dosage size (grams) (puffs) Cost 1 Beta-adrenergics Albuterol ...
Salmeterol xinafoate (Serevent - Allen & Hanburys), a long-acting β 2 -selective adrenergic agonist for inhalation, has been approved by the US Food and Drug Administration for maintenance treatment of asthma, with or without concurrent use of inhaled corticosteroids. Salmeterol is not recommended for acute treatment of bronchospasm.
Med Lett Drugs Ther. 1994 Apr 29;36(921):37-8 |  Show IntroductionHide Introduction

Immune Globulin IV for Prevention of RH Isoimmunization and for Treatment of ITP

   
The Medical Letter on Drugs and Therapeutics • Jan 19, 1996  (Issue 966)
OF U.S. AND INTERNATIONAL COPYRIGHT LAWS COST OF Rh IMMUNOPROPHYLAXIS IN PREGNANCY Drug Route Dosage 1 ...
immune globulin (human) has been available for many years in an intramuscular (IM) formulation for prevention of Rh isoimmunization in pregnant Rh-negative women (Medical Letter, 16:3, 1974). Recently, the US Food and Drug Administration (FDA) approved the first intravenous (IV) immune globulin preparation (WinRho SD - Univax), not only for preventing Rh isoimmunization, but also for treatment of immune thrombocytopenic purpura (ITP) in Rh-positive patients.
Med Lett Drugs Ther. 1996 Jan 19;38(966):6-8 |  Show IntroductionHide Introduction

Radiofrequency Catheter Ablation for Treatment of Cardiac Arrhythmias

   
The Medical Letter on Drugs and Therapeutics • Apr 26, 1996  (Issue 973)
with no recurrences during 1 to 16 months of follow-up (M Haissaguerre, Circulation, 85:2162, 1992). A second study ...
In recent years, selective destruction of cardiac tissue by radiofrequency energy has become a routine procedure for treatment of some types of cardiac arrhythmias, particularly supraventricular tachycardias (MM Scheinman, Pacing Clin Electrophysiol, 18:1474, 1995).
Med Lett Drugs Ther. 1996 Apr 26;38(973):40-2 |  Show IntroductionHide Introduction

Over-the-counter (OTC) Cough Remedies

   
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001  (Issue 1100)
. AND INTERNATIONAL COPYRIGHT LAWS 23 SOME OVER-THE-COUNTER COUGH REMEDIES 1 Decongestant/ Product Cough ...
The number of cough remedies available in the USA continues to multiply, but most products contain the same or similar ingredients in varying combinations. Most acute coughs do not require treatment with drugs, especially in children, and suppression of a productive cough may be harmful.
Med Lett Drugs Ther. 2001 Mar 19;43(1100):23-5 |  Show IntroductionHide Introduction

Valdecoxib (Bextra) - a New Cyclooxygenase-2 Inhibitor

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2002  (Issue 1129)
, selective COX-2 inhibitors do not inhibit COX-1, which protects the gastric mucosa, and therefore should ...
Valdecoxib (Bextra - Pharmacia/Pfizer), a selective cyclooxygenase (COX-2) inhibitor similar to celecoxib (Celebrex) and rofecoxib (Vioxx), was recently approved by the FDA for treatment of osteoarthritis, rheumatoid arthritis and primary dysmenorrhea.
Med Lett Drugs Ther. 2002 Apr 29;44(1129):39-41 |  Show IntroductionHide Introduction

Alosetron (Lotronex) revisited

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2002  (Issue 1136)
, with an elimination half-life of about 1.5 hours. Plasma concentrations of alosetron are higher in women than in men ...
The FDA recently announced that it will permit reintroduction of alosetron hydrochloride (Lotronex - GlaxoSmithKline) for treatment of irritable bowel syndrome (IBS). The drug was previously withdrawn from the market because of severe gastrointestinal toxicity. The reintroduced drug will have a 50% lower starting dose, a narrower indication and some other marketing restrictions (www.fda.gov/cder/drug/infopage/lotronex/lotronex.htm).
Med Lett Drugs Ther. 2002 Aug 5;44(1136):67-8 |  Show IntroductionHide Introduction

Insulin-Sensitizing Drugs for Polycystic Ovary Syndrome

   
The Medical Letter on Drugs and Therapeutics • Apr 28, 2003  (Issue 1155)
from The Medical Letter 2002; 1:1), metformin (Glucophage, and others) decreases hepatic glucose output ...
Polycystic ovary syndrome (PCOS), an endocrine abnormality characterized by hyperandrogenism and anovulation, affects 5-10% of women of reproductive age in the US. It is often accompanied by obesity and insulin resistance. In recent years, antidiabetic drugs, although not approved for such use by the FDA, have been tried for treatment of this disorder. This review describes the effectiveness of metformin and the thiazolidinediones in women with PCOS. Also included is a dosage and cost table for some insulin-sensitizing drugs.
Med Lett Drugs Ther. 2003 Apr 28;45(1155):35-6 |  Show IntroductionHide Introduction

Sildenafil for Pulmonary Hypertension

   
The Medical Letter on Drugs and Therapeutics • Mar 01, 2004  (Issue 1177)
to standard treatment with diuretics and warfarin and, in 1 patient, a calcium-channel blocker, found ...
Several recent case reports suggest that oral sildenafil may be effective for treatment of pulmonary arterial hypertension (PAH). Sildenafil is currently marketed as Viagra for treatment of erectile dysfunction (Medical Letter 1998; 40:51).
Med Lett Drugs Ther. 2004 Mar 1;46(1177):18-9 |  Show IntroductionHide Introduction

Topical Sertaconazole (Ertaczo) -- Another Azole for Tinea Pedis

   
The Medical Letter on Drugs and Therapeutics • Jun 21, 2004  (Issue 1185)
alone. Two weeks after completion of therapy, 13.1% (13/99) and 27.2% (28/103) of patients treated ...
Sertaconazole nitrate (Ertaczo - OrthoNeutrogena), an imidazole antifungal similar to clotrimazole and miconazole, has been approved by the FDA as a 2% cream for topical treatment of interdigital tinea pedis infection. It has been available in Europe for many years.
Med Lett Drugs Ther. 2004 Jun 21;46(1185):50-2 |  Show IntroductionHide Introduction

L-Carnitine

   
The Medical Letter on Drugs and Therapeutics • Nov 22, 2004  (Issue 1196)
of primary carnitine deficiency since 1986. 1 Products containing levocarnitine and its synthetic ...
Carnitine is a naturally occurring amino acid derivative essential for transport of long-chain fatty acids into mitochondria. It is advertised on the Internet as a dietary supplement that can promote weight loss, increase energy, enhance athletic performance and slow aging. Levocarnitine (Carnitor - Sigma-Tau) has been FDA approved for oral and parenteral treatment of primary carnitine deficiency since 1986. Products containing levocarnitine and its synthetic derivative acetyl-L-carnitine are available as dietary supplements in the US.
Med Lett Drugs Ther. 2004 Nov 22;46(1196):95-6 |  Show IntroductionHide Introduction